Carlo M. Cipolla

TL;DR: TnI release pattern after high-dose chemotherapy identifies patients at different risks of cardiac events in the 3 years thereafter, and stratification allows the monitoring program and to plan, in selected patients, preventive strategies aimed at improving clinical outcome.

TL;DR: In patients with aggressive malignancies who are undergoing high-dose chemotherapy, even minimal elevation of troponin I (TnI) is associated with late left ventricular dysfunction as discussed by the authors.

TL;DR: The elevation of cTnI in patients undergoing HDC for aggressive malignancies accurately predicts the development of future LVEF depression and can be considered a sensitive and reliable marker of acute minor myocardial damage with relevant clinical and prognostic implications.

TL;DR: Persistently increased NT-proBNP early after administration of HDC is strongly associated with development of cardiac dysfunction, and has important implications for identifying patients at risk of developing chemotherapy-induced cardiotoxicity.

TL;DR: The study indicates that hemofiltration may be a short-term treatment for refractory cardiac insufficiency with overhydration; a filtration rate of 500 ml/hour is effective and safe; and the central venous pressure May be a reliable guide to volume subtraction.